Detalhe da pesquisa
1.
Inflammation in background cirrhosis evokes malignant progression in HCC development from HCV-associated liver cirrhosis.
Scand J Gastroenterol
; 48(6): 729-35, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23556482
2.
Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
Cancer Epidemiol Biomarkers Prev
; 14(1): 164-9, 2005 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15668491
3.
Serum alanine aminotransferase levels and survival after hepatectomy in patients with hepatocellular carcinoma and hepatitis C virus-associated liver cirrhosis.
Cancer Sci
; 94(12): 1083-90, 2003 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-14662024
4.
[A case of advanced pancreatic cancer showing remarkable response to gemcitabine treatment].
Gan To Kagaku Ryoho
; 30(9): 1333-6, 2003 Sep.
Artigo
em Japonês
| MEDLINE | ID: mdl-14518416
5.
Severe inflammation in the background liver cirrhosis correlates with the development of poorly differentiated HCC in HCV-associated liver cirrhosis.
Intern Med
; 51(18): 2495-501, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22989817
6.
Sustained low alanine aminotransferase levels can predict the survival for 10 years without hepatocellular carcinoma development in patients with hepatitis C virus-associated liver cirrhosis of child stage A.
Intervirology
; 47(2): 65-71, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15192269
7.
Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis.
Cancer
; 94(6): 1787-95, 2002 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11920542